Abstract Dapagliflozin [Farxiga®(USA); Forxiga®(EU)], a sodium–glucose cotransporter 2
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …

Heart failure (HF) continues to be a major global health problem with a notable impact in
terms of morbidity and mortality and so, in consequence, with a large unmet necessity for …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background: In patients with heart failure (HF) and reduced ejection fraction (HFrEF) with or
without type 2 diabetes mellitus, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) …

The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Background Several clinical trials of dapagliflozin in patients with type 2 diabetes mellitus
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …